GeoVax Labs (NASDAQ: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer reported the U.S. Patent and Trademark Office has issued Patent No. 11,311,612 to GeoVax, pursuant to the Company’s patent application No. 16/648,693 titled “Compositions and Methods for Generating an Immune Response to Treat or Prevent Malaria.” In general, the claims granted in the patent cover GeoVax’s modified vaccinia Ankara (MVA) vector expressing certain antigens from the malaria parasite. GOVX CEO David Dodd commented, “We remain strongly committed to advancing innovation towards improving public health worldwide and this patent reflects a potentially significant advance relative to malaria prevention. Our development priorities continue to be our COVID-19 vaccine, currently in Phase 2 clinical trials, and our cancer immunotherapy program, with Gedeptin® as our lead product in a Phase 1/2 clinical trial for Head and Neck cancer. However, developing vaccines against global public health threats such as malaria, is also part of our longer-term focus. Our goals include developing such vaccines that are affordable, highly effective, safe, and can be distributed and administered across various regions of the world in a simple manner.”
https://finance.yahoo.com/news/biomed-stocks-move-geovax-labs-150000195.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.